ArticleFrontiers in cellular and infection microbiology2022
Harmine, an inhibitor of the type III secretion system of
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Houttuynia cordata extract protects against Salmonella infection by targeting type III secretion system 1.Poultry science · 2026Article
- Harmine Targets Peroxiredoxin 6 to Enhance Macrophage Immunity AgainstAntioxidants (Basel, Switzerland) · 2026Article
- Isopropyl paraben targets type III secretion to inhibitVirulence · 2025Article
- Targeting Type III Secretion System usingIndian journal of microbiology · 2025Review
- Discovery of synthetic small molecules targeting the central regulator ofScience advances · 2025Article
- Harmine alleviates LPS-induced acute lung injury by inhibiting CSF3-mediated MAPK/NF-κB signaling pathway.Respiratory research · 2025Article
- Purpurin suppresses Salmonella invasion of host cells by reducing the secretion of T3SS-1 effector proteins.Scientific reports · 2025Article
- Naringenin targets FimZ to regulate type I fimbriae and reduce the virulence ofFrontiers in cellular and infection microbiology · 2025Article
- A Supramolecular Antibiotic Targeting Drug-ResistantACS applied materials & interfaces · 2024Article
- Review
- Fisetin inhibitsMicrobiology spectrum · 2024Article
- A screening identifies harmine as a novel antibacterial compound againstFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New therapeutic strategies for clinical
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.